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Cyclosporine is a potent immunosuppressive drug, 
which has dose-related nephrotoxicity. In renal trans-
plantation, the differentiation between rejection and 
toxicity is dilf"lCult and even with the aid of blood levels 
of the drug, it may be difficult to establish a chronic 
maintenance dose. Long-term survivors after liver 
transplantation can provide modes with which to estab-
lish maintenance doses, as these are dictated by neph-
rotoxicity in these patients. Twenty-nine liver trans-
plant patients who survived one year or more were 
followed for changes in their cyclosporine doses. Daily 
oral cyclosporine dose, BUN, serum creatinine and bil-
irubin were monitored. The reductions in cyclosporine 
were dictated almost entirely by the findings of neph-
rotoxicity. 
Cyclosporine is a potent immunosuppressive agent that has 
dose-related nephrotoxicity (1-3). In renal transplantation, 
differentiation between rejection and drug toxicity is often 
difficult. Even with the aid of blood levels of the drug it may 
be difficult to establish a chronic maintenance dose. Long-term 
survivors after liver transplantation can provide ideal models 
with which to establish maintenance doses of cyclosporine, 
because these are dictated by nephrotoxicity. 
MATERIALS AND METHODS 
Case materials. From March, 1980 to May 1982, 67 patients 
received orthotopic liver allografts under cyclosporine-Iow-
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TABLE 1. Indications for transplantation in adult patients (2:19 
years) from March 1980 to May 1982 
Indications 
Chronic aggressive hepatitis 
Malignancy" 
Primary biliary cirrhosis 
Secondary biliary cirrhosis 
2 trauma 
1 Caroli 
















• One patient in each group had had previous right hepatic triseg-
mentectomy (at 1 and 4th years earlier). At transplantation, the regen-
erated left-lateral segment was replaced with a whole liver. 
dose-steroid therapy. Forty-one of the 67 recipients lived one 
year or longer as of May, 1983 (one-year actual survival of 
61%). One patient who was dying of recurrent cholangiocarci-
noma was excluded from analysis because immunosuppression 
had been stopped. 
Indications for orthotopic liver transplantation are shown in 
Tables 1 and 2. Common indications in adults were chronic 
aggressive hepatitis, primary liver malignancy, and primary 
biliary cirrhosis. Common diagnoses in children were biliary 
atresia and alpha-1-antitrypsin deficiency disease. 
Twenty-six of the 41 one-year survivors were adults over the 
age of 18 years, weighing more than 40 kg; 6 were school 
children and adolescents aged 7-17, weighing 21-40 kg; and 
nine were infants and preschool children under the age of 7 
years and below the weight of 20 kg. 
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Cyclosporine dose. All patients received their first doses of 
cyclosporine several hours before transplantation, either 17.5 
mg/kg by mouth or 5 mg/kg i.v. (4). After transplantation, 5-6 
mg/kg/day of cyclosporine was given Lv. in two divided doses 
TABLE 2. Indications for transplantation in pediatric patients (:::s18 




Chronic aggressive hepatitis 
Byler's disease' 
Secondary biliary cirrhosis" 
Budd-Chiari syndrome 
Neonatal hepatitis 
Subacute Wilson's diseaseb 
Tyrosinemiab 
Type I glycogen storage diseaseb 
Sea-blue histiocyte syndromeb 
Total 













b Inborn errors of metabolism; the children with tyrosinemia and 
sea-blue histiocyte syndrome had incidental hepatomas in their cir-
rhotic livers. 
, Diagnosis equivocal in one case. 
d Choledochal cyst with multiple operations. 
until the oral dose was tolerated. Within a few days 17.5 mg/ 
kg/day of cyclosporine in two divided doses was administered 
orally. The dose of cyclosporine was reduced in the presence of 
renal failure soon after transplant, or the dose was adjusted to 
maintain near-normal BUN (less than 40 mg%) and serum 
creatinine (less than 2 mg%). 
Steroid dose. In adults 1 g methylprednisolone was given i.v. 
intraoperatively. After the operation a 5-day burst of predni-
sone or methylprednisolone was begun at 200 mg/day, and the 
dose was reduced by daily increments of 40 mg to an initial 
daily maintenance dose of 20 mg/day (4). 
In children 250 mg or 500 mg of methylprednisolone was 
given i.v. intraoperatively. After the operation, a 5-day burst of 
prednisone or methylprednisolone was begun at 100 mg/day, 
and the dose was reduced by daily increments of 20 mg to an 
initial daily maintenance dose of 10 mg/day. Further downward 
adjustment of steroid dosage was made in smaller children and 
infants (4). 
In case of acute rejection a bolus of i.v. steroid therapy or a 
5-day burst of prednisone, or both, was repeated. 
RESULTS 
Daily oral cyclosporine dose, BUN, serum creatinine, and 
total bilirubin before liver transplantation, at I, 3, 6, 9, and 12 
months are shown in Tables 3, 4, and 5. The daily oral dose of 
cyclosporine at 12 months after liver transplantation to avoid 
TABLE 3. Daily oral cyclosporine dose, BUN, serum creatinine, and total bilirubin before transplant, at I, 3, 6, 9, and 12 months among 25 
adult recipients (age ~19 years old and body weight ~41 kg) 
Pre-TX· 1 Month 3 Months 6 Months 9 Months 12 Months 
Cyclosporine (mg/kg/day 17.5 12.5±4.3 10.8±6.7 8.2±3.6 7.6±3.5 6.7±2.2 
p.o.) 
BUNmg% 18.1±19.8 37.3±28.8 36.9±16.6 33.9±1l.1 36.3±12.1 30.6±1l.7 
Creatinine mg% 1.2±O.8 2.2±2.2 l.S±O.7 1.6±O.6 1.9±O.7 l.6±O.4 
Bilirubin mg% 9.9±12,4 3.6±3.2 3.0±5.7 1.3±1.7 2.6±5.8b l.4±7.2 
(Mean±SD) (Mean±SD) (Mean±SD) (Mean±SD) (Mean±SD) (Mean±SD) 
• Before transplantation. 
b High values were influenced by two patients, one of whom had chronic rejection and another of whom had biliary obstruction resulting from 
recurrent cancer. 
TABLE 4. Daily oral cyclosporine dose, BUN, serum creatinine, and total bilirubin before transplant, at I, 3, 6, 9, and 12 months among 6 
school-aged pediatric recipients (age between 7 and 18 years old, and body weight between 21 and 40 kg) 
Pre-TX· 1 Month 3 Months 6 Months 9 Months 12 Months 
Cyclosporine (mg/kg 17.5 12.1l±3.1 12.7±5.6 10.5±2.8 8.9±5.6 9.B±2.7 
p.o.) 
BUNmg% 32.S±36.2 32.0±14.8 27.7±12.0 26.B±13.6 24.0±13.5 25.5±21.9 
Creatinine mg% 1.6±1.6 1.0±O.9 0.8±O.2 0.9±O.4 1.0±0,4 0.8±O.4 
Bilirubin mg% 19.0±IS.8 3.8±4.8 l.S±1.2 l.l±O.7 1.0±0.96 1.0±0.9 
(Mean±SD) (Meao±SD) (Mean:l:SD) (Mean±SD) (Mean±SD) (Mean±SD) 
• Before transplantation. 
TABLE 5. Daily oral cyc10sp0rine dose, BUN, serum creatinine, and total bilirubin before transplant, at I, 3, 6, 9, and 12 months among 9 pre-
school-aged pediatric recipients (age:s6 years old and body weight :s20'kg) 
Pre-TX· 1 Month 3 Months 6 Months 9 Months 12 Months 
Cyclosporine (mg/kg/day 17.5 17.1±3.9 17.8±5.6 14.7±5.3 12.1±3.8 11.l±2.2 
p.o.) 
BUNmg% 14.4±6.6 18.1±13.5 15.7±4.7 17.3±5.3 23.9±12.7 20.7±7.7 
Creatinine mg% 0.7±O.6 0.4±O.2 O.4±O.2 0.5±O.2 0.S±O.2 0.5±O.1 
Bilirubin mg% 1l.7±11.6 3.6±5.6 1.2±1.2 O.6±O.3 0.6±O.3 O.S±O.2 
(Mean±SD) (Mean±SD) (Mean±SD) (Mean±SD) (Mean±SD) (Mean±SD) 
• Before transplantation. 
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nephrotoxicity was 6.7 mg±2.2 mg/kg/day for adults, 9.S±2.7 
mg/kg/day for school children and adolescents, and 11.05 ± 
2.2. mg/kg/day for infants and preschool children. Pediatric 
patients could tolerate larger doses of cyclosporine than adult 
patients. 
DISCUSSION 
Acute and chronic nephrotoxicity of cyciosporine has been a 
clinical problem since the introduction of this potent immuno-
suppressive agent to organ transplantation. Clinical differen-
tiation of nephrotoxicity of cyclosporine from renal graft rejec-
tion is quite important but often difficult even with the meas-
urement of drug blood levels. Despite the need, no dosage guide 
has been established for long-term use of cyciosporine to avoid 
nephrotoxicity. Survivors of extrarenal organ transplantation, 
such as liver transplantation, provide this information, because 
renal functions of these patients have mostly been dictated by 
the nephrotoxicity of cyciosporine. The dosage guide provided 
by this study should be useful in long-term management of 
patients with cyciosporine. 
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